ACN00177 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
337	Homocystinuria	2

337. Homocystinuria

---

Clinical trials : 16 /  Drugs : 19 - (DrugBank : 7) / Drug target genes : 2 - Drug target pathways : 23

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05154890 (ClinicalTrials.gov)	May 13, 2021	20/8/2021	A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency	A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine ß-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177	Homocystinuria Due to Cystathionine Beta-Synthase Deficiency	Drug: Pegtarviliase	Aeglea Biotherapeutics	NULL	Recruiting	12 Years	N/A	All	36	Phase 1/Phase 2	United States;Australia;United Kingdom
2	EUCTR2019-004791-19-GB (EUCTR)	11/05/2020	14/01/2020	A Phase 1/2 Study of ACN00177 in Subjects With Homocystinuria Due to Cystathionine ß-Synthase (CBS) Deficiency	A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine ß-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177 - SA notification 100D New site and PI	Homocystinuria Due to Cystathionine ß-Synthase (CBS) Deficiency MedDRA version: 20.0;Level: PT;Classification code 10020365;Term: Homocystinuria;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]	Product Code: ACN00177	Aeglea Biotherapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	25	Phase 1	United Kingdom